Back to mobile site

UBS Starts CymaBay Therapeutic (CBAY) at Buy, 'Confidence in Ph3 success'

August 14, 2023 4:30 AM EDT Send to a Friend
(Updated - August 14, 2023 4:49 AM EDT)

UBS analyst Eliana Merle initiates coverage on CymaBay Therapeutic (NASDAQ: CBAY) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login